## **IN THE CLAIMS:**

This listing of claims will replace all prior versions and listings of claims in the application:

- 1. (Currently amended) A method of reducing or alleviating one or more side effects of anti-retroviral drug therapy delaying viral rebound during interruption of anti-retroviral drug treatment comprising administering to [[a]] an HIV infected subject exhibiting a low retroviral load a poxvirus an avipox vector encoding an HIV antigen of the retrovirus or the retrovirus antigen and IFNγ a cytokine, or a functional homolog, derivative, part or analog of the retrovirus antigen and/or the cytokine, in conjunction with interrupted anti-retroviral drug therapy wherein the antigen or the antigen and the IFNγ cytokine are expressed in the subject and are effective in maintaining or prolonging a low retroviral load in the subject for a period of time and are effective in preventing, reducing or delaying viral rebound during interruption of anti-retroviral drug treatment.
- 2. (Canceled)
- 3. (Currently amended) The method of claim 1 [[or 2]], wherein the vector is administered to a subject exhibiting a low retroviral [[viral]] load as a result of <u>or prior to</u> antiretroviral drug therapy.
- 4. (Currently amended) The method of claim 1 [[or 2]], wherein the vector is administered to a subject exhibiting a low retroviral load prior to commencement of anti-retroviral drug therapy.
- 5. (Canceled)
- 6. (Canceled)
- 7. (Currently amended) The method of any one of claims 1 or 3-4 [[to 6]], wherein the

retrovirus antigen is encoded by a coding region selected from gag, env, pol and pro coding regions.

- 8. (Original) The method of claim 7, wherein the retrovirus antigen is encoded by gag and/or pol coding regions.
- 9. (Original) The method of claim 8, wherein the retrovirus antigen is encoded by gag and pol coding regions of HIV.
- 10. (Canceled)
- 11. (Currently Amended) The method of claim [[10]]1, wherein the avipox virus vector is a fowlpox virus vector.

## 12-46. (Canceled)

- 47. (Withdrawn) A recombinant poxvirus vector comprising a sequence of nucleotides encoding a retrovirus antigen or a functional homolog, derivative, part or analog thereof, and a sequence of nucleotides encoding a cytokine or a functional homolog, derivative, part or analog thereof, when used in conjunction with interrupted anti-retroviral drug therapy to maintain or prolong a low retroviral load in a subject and to prevent, reduce or delay viral rebound during interruption of anti-retroviral drug treatment in a subject.
- 48. (Withdrawn) A recombinant poxvirus vector comprising a sequence of nucleotides encoding a retrovirus antigen or a functional homolog, derivative, part or analog thereof, and a sequence of nucleotides encoding a cytokine or a functional homolog, derivative, part or analog thereof, when used for reducing or alleviating one or more side effects of anti-retroviral drug therapy.
- 49. (Withdrawn) The recombinant poxvirus vector of claim 48, when used for maintaining

or prolonging a low retroviral load in the subject during anti-retroviral treatment interruption and for reducing or alleviating one or more side effects of anti-retroviral drug therapy.

- 50. (Withdrawn) The recombinant poxvirus vector of claims 47, 48 or 49, wherein the retrovirus is HIV.
- 51. (Withdrawn) The recombinant vector of claims 47, 48, 49 or 50, wherein the cytokine is selected from IFNγ, IL-12, IL-2, TNF and IL-6.
- 52. (Withdrawn) The recombinant vector of claim 51, wherein the cytokine is IFNy.
- 53. (Previously Withdrawn) The recombinant vector of claim 52, wherein the IFNγ comprises the amino acid sequence set forth in SEQ ID NO: 6 or an amino acid sequence having at least about 60% similarity thereto.
- 54. (Withdrawn) The recombinant vector of claim 52, wherein IFNγ is encoded by a sequence of nucleotides set forth in SEQ ID NO: 5 or a sequence of nucleotides encoding a functional homolog or derivative thereof having at least 60% similarity thereto or a sequence which hybridises thereto or to a complementary form thereof under conditions of medium stringency.
- 55. (Withdrawn) The recombinant vector of any one of claims 47 to 54, wherein the retrovirus antigen is encoded by a coding region selected from *gag*, *env*, *pol* and *pro* coding regions.
- 56. (Withdrawn) The recombinant vector of claim 55, wherein the retrovirus antigen is encoded by gag and/or pol coding regions.
- 57. (Withdrawn) The recombinant vector of claim 56, wherein the retrovirus antigen is

encoded by gag and pol coding regions of HIV.

- 58. (Withdrawn) The recombinant vector of claim 57, wherein the retrovirus antigens encoded by gag and pol comprise the amino acid sequence set forth in SEQ ID NO: 2 or a functional homolog, part or derivative thereof or a sequence of amino acids having at least 60% similarity thereto, and SEQ ID NO: 4 or a functional homolog, part or derivative thereof or a sequence of amino acids having at least 60% similarity thereto, respectively.
- 69. (Withdrawn) The recombinant vector of claim 57, wherein the retrovirus antigen encoded by gag is encoded by a sequence of nucleotides set forth in SEQ ID NO: 1 or a sequence of nucleotides encoding a functional homolog, part or derivative thereof having at least 60% similarity thereto after optimal alignment or a sequence which hybridises thereto or to a complementary form thereof under conditions of medium stringency, and wherein the retrovirus antigen encoded by pol is encoded by a sequence of nucleotides set forth in SEQ ID NO: 3 or a sequence of nucleotides encoding a functional homolog, part or derivative thereof having at least 60% similarity thereto after optimal alignment or a sequence which hybridises thereto or to a complementary form thereof under conditions of medium stringency.
- 60. (Withdrawn) The recombinant vector of any one of claims 47 to 59, wherein the poxvirus vector is an avipox virus vector.
- 61. (Withdrawn) The recombinant vector of claim 60, wherein the avipox virus vector is a fowlpox virus vector.
- 62. (Withdrawn) The recombinant vector of claim 61, wherein the insertion site in the fowlpox vector comprises the sequence of nucleotides set forth in SEQ ID NO: 7.